000143753 001__ 143753
000143753 005__ 20240229121829.0
000143753 0247_ $$2doi$$a10.1024/0301-1526/a000762
000143753 0247_ $$2pmid$$apmid:30421661
000143753 0247_ $$2ISSN$$a0251-1029
000143753 0247_ $$2ISSN$$a0301-1526
000143753 0247_ $$2ISSN$$a1664-2872
000143753 0247_ $$2altmetric$$aaltmetric:53432598
000143753 037__ $$aDKFZ-2019-01322
000143753 041__ $$aeng
000143753 082__ $$a610
000143753 1001_ $$aPeters, Andreas S$$b0
000143753 245__ $$aEffect of metformin treatment in patients with type 2 diabetes with respect to glyoxalase 1 activity in atherosclerotic lesions.
000143753 260__ $$aGöttingen [u.a.]$$bHuber$$c2019
000143753 3367_ $$2DRIVER$$aarticle
000143753 3367_ $$2DataCite$$aOutput Types/Journal article
000143753 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1582280448_27335
000143753 3367_ $$2BibTeX$$aARTICLE
000143753 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143753 3367_ $$00$$2EndNote$$aJournal Article
000143753 520__ $$aThe enzyme glyoxalase1 (GLO1) is the main opponent in the degradation of the reactive metabolite methylglyoxal (MG), which by glycation of macromolecules is involved in atherogenesis. Reduced GLO1-activity in atherosclerotic tissue is known to be associated with diabetes. It has been shown that treatment of patients with type 2 diabetes with metformin leads to increased GLO1-activity in peripheral-blood-cells. The aim of this study was to evaluate whether metformin treatment increases GLO1-activity in atherosclerotic lesions of patients with type 2 diabetes.Patients with type 2 diabetes and carotid artery disease were included into the study prospectively. Type of diabetes-medication was documented upon admission along with demographic and clinical history. Using shock frozen endarterectomy-derived carotid artery plaques, GLO1-activity as well as protein expression was measured by a spectophotometric assay and western-blotting respectively.33 patients (76 % male, mean age 71 years) were included into the study and were divided according to treatment with metformin or not (15 vs. 18 patients). GLO1-activity was increased by the factor 1.36 when treated with metformin - however, not significantly (0.86 vs. 0.63 U/mg, p = 0.056). Normalisation of GLO1-activity onto GLO1-expression level lead to a significant increase by more than twofold (8.48 vs. 3.85, p = 0.044) while GLO1-protein levels did not differ significantly. GLO1-activity correlated positively with increasing HbA1c, especially under metformin treatment.Treatment with metformin in patients with type 2 diabetes is associated with enhanced GLO1-activity in atherosclerotic lesions. Regarding the macro- and microvascular complications in these patients further studies are needed to gain more insight into the effect of metformin on the GLO/MG system.
000143753 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000143753 588__ $$aDataset connected to CrossRef, PubMed,
000143753 650_7 $$09100L32L2N$$2NLM Chemicals$$aMetformin
000143753 650_7 $$0EC 4.4.1.5$$2NLM Chemicals$$aLactoylglutathione Lyase
000143753 7001_ $$aWortmann, Markus$$b1
000143753 7001_ $$aFleming, Thomas H$$b2
000143753 7001_ $$0P:(DE-HGF)0$$aNawroth, Peter P$$b3
000143753 7001_ $$0P:(DE-HGF)0$$aBruckner, Thomas$$b4
000143753 7001_ $$aBöckler, Dittmar$$b5
000143753 7001_ $$aHakimi, Maani$$b6
000143753 773__ $$0PERI:(DE-600)2082843-3$$a10.1024/0301-1526/a000762$$gVol. 48, no. 2, p. 186 - 192$$n2$$p186 - 192$$tVasa$$v48$$x1664-2872$$y2019
000143753 909CO $$ooai:inrepo02.dkfz.de:143753$$pVDB
000143753 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143753 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$aExternal Institute$$b4$$kExtern
000143753 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000143753 9141_ $$y2019
000143753 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143753 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143753 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bVASA : 2017
000143753 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143753 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143753 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143753 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143753 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143753 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143753 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143753 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000143753 9201_ $$0I:(DE-He78)A170-20160331$$kA170$$lMolekulare Stoffwechselkontrolle$$x0
000143753 980__ $$ajournal
000143753 980__ $$aVDB
000143753 980__ $$aI:(DE-He78)A170-20160331
000143753 980__ $$aUNRESTRICTED